Could Skinvisible (SKVI) Have the Answer to a Potential New Global Flu Pandemic?
- Skinvisible Pharmaceuticals, Inc. is making confident steps toward the large-scale distribution of its hand sanitizer in China
- Clinical studies show that frequent hand sanitization is the only effective non-pharmaceutical measure for influenza prevention
- Worries about the spread of avian influenza and its high mortality rate have triggered the introduction of more rigorous prophylactic measures and market growth
H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://nnw.fm/Aj1UB). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI) subsidiary Skinvisible Pharmaceuticals, Inc. is one of them. In June, Skinvisible announced the first international sale of DermSafe in China – a country that’s known to have the first reported cases of human avian influenza infections.
As winter approaches, researchers warn that the risk of flu viruses spreading increases. H7N9 infections have been sporadic so far, but the virus has been mutating (http://nnw.fm/l1IzO). This would be its sixth year of existence, and, over this period of time, avian influenza has had a mortality rate of 36 percent among 1,562 lab-confirmed infections. The fifth wave of the viral infection (starting in 2017) has been the deadliest one yet. Out of 764 infected individuals, 250 died because of the virus.
Virus mutations, more serious epidemics and their consequences are making researchers work hard on the creation of flu prevention products. Influenza vaccines are becoming more popular than ever before, with a projected growth in the U.S. from 147.8 million doses in 2016 to 179 million doses in 2017 (http://nnw.fm/IQ9yA). The current value of the market is estimated at $4 billion.
Apart from vaccination, the use of the right personal hygiene products is another highly effective way to prevent the spread of flu viruses, including H7N9. According to a report presented in the BMC Public Health Journal, frequent hand washing and sanitization (at least five times per day) is the only non-pharmaceutical prophylactic measure that is a statistically-significant protective factor in the case of pediatric influenza (http://nnw.fm/a4t7X).
Hand sanitizers like Skinvisible’s DermSafe could be one of the answers when it comes to influenza prevention. Independent studies of the product suggest that DermSafe kills germs immediately upon application, and it also provides four additional hours of protection upon topical use. In addition to its powerful anti-bacterial/viral properties, DermSafe is free from alcohol. This means that it doesn’t have a drying effect, and it feels pleasant on the skin.
DermSafe’s formulation features chlorhexidine gluconate in a four-percent concentration. This ingredient has proven its ability to kill both gram-positive and gram-negative bacteria, as well as viruses. It also offers long-lasting protection from germs when human skin comes in contact with hard surfaces. Through clinical tests, it’s been proven that the active ingredient in DermSafe is effective against H7N9, as well as H1N1 – the swine flu virus.
Since DermSafe is approved for sale by Health Canada, prior to its product launch in China, DermSafe was used by the Canadian Olympic team during the games in Rio. The Olympic team was capable of successfully addressing concerns stemming from water quality through the use of the hand sanitizer. The Canadian Olympic team will also be protected by DermSafe in February 2018 at the Winter Olympic Games in South Korea.
Skinvisible Pharmaceuticals is looking for opportunities to expand the distribution of DermSafe globally. In 2013, the Company obtained registration rights for DermSafe in Belgium. Through this designation, the hand sanitizer can be registered and distributed in most EU countries. The larger long-term strategy includes the effective distribution of the company’s product globally.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Skinvisible Pharmaceuticals, Inc. is making confident steps toward the large-scale distribution of its hand sanitizer in China
- Clinical studies show that frequent hand sanitization is the only effective non-pharmaceutical measure for influenza prevention
- Worries about the spread of avian influenza and its high mortality rate have triggered the introduction of more rigorous prophylactic measures and market growth
H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://nnw.fm/Aj1UB). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI) subsidiary Skinvisible Pharmaceuticals, Inc. is one of them. In June, Skinvisible announced the first international sale of DermSafe in China – a country that’s known to have the first reported cases of human avian influenza infections.
As winter approaches, researchers warn that the risk of flu viruses spreading increases. H7N9 infections have been sporadic so far, but the virus has been mutating (http://nnw.fm/l1IzO). This would be its sixth year of existence, and, over this period of time, avian influenza has had a mortality rate of 36 percent among 1,562 lab-confirmed infections. The fifth wave of the viral infection (starting in 2017) has been the deadliest one yet. Out of 764 infected individuals, 250 died because of the virus.
Virus mutations, more serious epidemics and their consequences are making researchers work hard on the creation of flu prevention products. Influenza vaccines are becoming more popular than ever before, with a projected growth in the U.S. from 147.8 million doses in 2016 to 179 million doses in 2017 (http://nnw.fm/IQ9yA). The current value of the market is estimated at $4 billion.
Apart from vaccination, the use of the right personal hygiene products is another highly effective way to prevent the spread of flu viruses, including H7N9. According to a report presented in the BMC Public Health Journal, frequent hand washing and sanitization (at least five times per day) is the only non-pharmaceutical prophylactic measure that is a statistically-significant protective factor in the case of pediatric influenza (http://nnw.fm/a4t7X).
Hand sanitizers like Skinvisible’s DermSafe could be one of the answers when it comes to influenza prevention. Independent studies of the product suggest that DermSafe kills germs immediately upon application, and it also provides four additional hours of protection upon topical use. In addition to its powerful anti-bacterial/viral properties, DermSafe is free from alcohol. This means that it doesn’t have a drying effect, and it feels pleasant on the skin.
DermSafe’s formulation features chlorhexidine gluconate in a four-percent concentration. This ingredient has proven its ability to kill both gram-positive and gram-negative bacteria, as well as viruses. It also offers long-lasting protection from germs when human skin comes in contact with hard surfaces. Through clinical tests, it’s been proven that the active ingredient in DermSafe is effective against H7N9, as well as H1N1 – the swine flu virus.
Since DermSafe is approved for sale by Health Canada, prior to its product launch in China, DermSafe was used by the Canadian Olympic team during the games in Rio. The Olympic team was capable of successfully addressing concerns stemming from water quality through the use of the hand sanitizer. The Canadian Olympic team will also be protected by DermSafe in February 2018 at the Winter Olympic Games in South Korea.
Skinvisible Pharmaceuticals is looking for opportunities to expand the distribution of DermSafe globally. In 2013, the Company obtained registration rights for DermSafe in Belgium. Through this designation, the hand sanitizer can be registered and distributed in most EU countries. The larger long-term strategy includes the effective distribution of the company’s product globally.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
